Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANS-6637 on Midazolam PK in Healthy Volunteers
NCT03831971Phase 1Completed
- Sponsor
- National Institutes of Health
- Start
- Mar 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ANS-6637 in opioid use disorder (OUD), sponsored by National Institutes of Health. Primary endpoint: Time to Maximum Concentration of Midazolam Alone at Day 1. Started Mar 2019; status: completed.
02
Drugs
ANS-6637
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03831971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03831971.